Scholarlink

<p>High-dose cytarabine has been the frontline therapy for the consolidation treatment of acute myeloid leukemia for many years. Current guidelines suggest that the combination of anthracyclines with high-dose cytarabine can be considered an option for consolidation therapy in certain patients. However, the research in this area is limited. This study aimed to investigate whether consolidation therapy with high doses of cytarabine in combination with idarubicin could result in better long-term survival. A total of 102 patients who achieved complete response and underwent consolidated treatment more than twice were included in the analysis. In this study, 49 patients received high-dose cytarabine alone for consolidation chemotherapy (HDAC group), and 53 patients received idarubicin in combination with high-dose cytarabine for consolidation chemotherapy (IHDAC group). The use of idarubicin in combination with high-dose cytarabine in consolidation therapy did not lead to a better long-term prognosis in patients than high-dose cytarabine alone. Patients treated with idarubicin required a significantly longer time to recover from agranulocytosis during hospitalization and had a higher incidence of infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月25日

查看全文
  • Bingxin Qian,
  • Guiqin Huang,
  • Xiaoya Cai,
  • Ying Liu,
  • Dengju Li,
  • Jin Yin

摘要

High-dose cytarabine has been the frontline therapy for the consolidation treatment of acute myeloid leukemia for many years. Current guidelines suggest that the combination of anthracyclines with high-dose cytarabine can be considered an option for consolidation therapy in certain patients. However, the research in this area is limited. This study aimed to investigate whether consolidation therapy with high doses of cytarabine in combination with idarubicin could result in better long-term survival. A total of 102 patients who achieved complete response and underwent consolidated treatment more than twice were included in the analysis. In this study, 49 patients received high-dose cytarabine alone for consolidation chemotherapy (HDAC group), and 53 patients received idarubicin in combination with high-dose cytarabine for consolidation chemotherapy (IHDAC group). The use of idarubicin in combination with high-dose cytarabine in consolidation therapy did not lead to a better long-term prognosis in patients than high-dose cytarabine alone. Patients treated with idarubicin required a significantly longer time to recover from agranulocytosis during hospitalization and had a higher incidence of infections.